Rigor Reviewed

Rigor-Reviewed Manuscript

Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N(2)M(2) umbrella trial.

Name: Αlpha¹ Rigor Record — Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N(2)M(2) umbrella trial.
Item: Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N(2)M(2) umbrella trial.
Rating: 100
Author: Αlpha¹

Wick W, Lanz LM, Wick A, Harting I, Dettmer S, Suwala AK, Ketter R, Tabatabai G, Seliger C, Glas M, Burger MC, Timmer M, Ringel FA, Mildenberger I, Schulz-Schaeffer WJ, Winkler F, König L, Herold-Mende C, Eisenmenger A, Pfister SM, Renovanz M, Bendszus M, Sahm F, Platten M, Kessler T

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.5★ (Weak), 0 critical, 4 high issues for “Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N(2)M(2) umbrella trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

CitationsCitations & links (capped) ×6−1★
IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Citations & links are capped at −1★ combined, however many are flagged.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 3 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 1/2a umbrella trial in glioblastoma. The paper demonstrates strong scientific premise, rigorous design, thorough ethical documentation, and adequate data availability. Minor reporting gaps include lack of explicit reporting guideline adherence and some copyedit issues, but no major rigor concerns.

Both reviewers independently scored all eight dimensions and agreed on all statuses. The study type is interventional (clinical trial). Verification components checked citations (6 not found in registry), statistics (2 tests consistent), reproducibility (links live), preregistration (ClinicalTrials.gov and EudraCT), and integrity (minor internal contradiction). The statistics coverage is partial; only a subset of tests were machine-verified.

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites multiple prior trials and molecular studies, acknowledges the failure of unselected targeted approaches, and provides a logical rationale for molecularly matched treatment. It also addresses limitations of prior research, such as the need for accurate MGMT testing and the importance of biomarker validation.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on glioblastoma molecular subtypes, targeted therapies, and the rationale for an umbrella trial design.

Evidence

direct quote[Main, paragraph 1]

“Trials aiming at replacing TMZ with targeted agents in not molecularly selected patient populations have failed to demonstrate relevant benefit to date”